GlassScriptPhysician profile
Matthew D Hulsey
NPI 1275573750
$1,107.65
in general payments reported to CMS, 2019-2025
17 companies · $78.82 in 2025
The $78.82 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $130 · 2021: $90.44 · 2022: $117 · 2023: $245 · 2024: $307 · 2025: $78.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $156.28 | 2024 | Aquabeam System |
| Astrazeneca Pharmaceuticals LP | $152.23 | 2023-2024 | Farxiga, Airsupra |
| Exact Sciences Corporation | $138.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $99.15 | 2019 | |
| Abbvie INC. | $98.60 | 2021-2023 | |
| Pfizer INC. | $84.87 | 2020-2023 | |
| Amgen INC. | $82.57 | 2020-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $65.61 | 2021-2022 | |
| Glaxosmithkline, LLC. | $53.54 | 2020-2022 | |
| Novo Nordisk INC | $44.06 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $32.12 | 2020 | |
| Lilly USA, LLC | $24.58 | 2020 | |
| Phadia US INC. | $20.74 | 2023 | Immunocap |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.14 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $15.05 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hulsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.